摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 12(S)-amino-4-methoxy-10-methyl-11-oxo-10-aza-2-oxatricyclo<12.2.2.2.13,7>nonadeca-3,5,7(19),14,16,17-hexaen-9(S)-carboxylate | 167467-04-1

中文名称
——
中文别名
——
英文名称
methyl 12(S)-amino-4-methoxy-10-methyl-11-oxo-10-aza-2-oxatricyclo<12.2.2.2.13,7>nonadeca-3,5,7(19),14,16,17-hexaen-9(S)-carboxylate
英文别名
——
methyl 12(S)-amino-4-methoxy-10-methyl-11-oxo-10-aza-2-oxatricyclo<12.2.2.2.1<sup>3,7</sup>>nonadeca-3,5,7(19),14,16,17-hexaen-9(S)-carboxylate化学式
CAS
167467-04-1
化学式
C21H24N2O5
mdl
——
分子量
384.432
InChiKey
PFGSKIBHMLZVLW-IRXDYDNUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.91
  • 重原子数:
    28.0
  • 可旋转键数:
    2.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    91.09
  • 氢给体数:
    1.0
  • 氢受体数:
    6.0

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    N-Desmethyl Derivatives of Deoxybouvardin and RA-VII: Synthesis and Evaluation
    摘要:
    The synthesis of the complete set of seven N-desmethyl derivatives of RA-VII (8) are described. Thus, the synthesis of the four 14-membered cycloisodityrosine derivatives 21-24 and their coupling with the two tetrapeptides 32 and 33 followed by formation of the 18-membered ring with macrocyclization provided the full set of seven desmethyl derivatives 14-20 of RA-VII (8). The solution phase conformational properties of 8 and 14-20 were examined by 1D and 2D H-1 NMR to reveal the role of N-methylation on the key conformational aspects of the natural agents. In contrast to each of the simple cycloisodityrosine derivatives 21-24 which adopt a single, rigid solution conformation possessing a secondary or tertiary trans amide central to the 14-membered ring, the natural agents including 8 adopt a single predominant solution conformation (83-88%) that corresponds closely to the X-ray structure conformation which possesses an inherently disfavored cis C-30-N-29 tertiary amide central to the 14-membered cycloisodityrosine subunit. Moreover, this cis amide is the predominant conformation (85-95%) observed with N-29-desmethyl RA-VII (14) indicating that even a secondary C-30-N-29 amide adopts this inherently disfavored cis amide stereochemistry. The minor conformation of 8 observed in solution (12-17%) is shown to be derived from a minor cis C-8-N-9 tertiary amide which was not observed with its conversion to a secondary amide. Both N-9-desmethyl RA-VII (15) and N-9,N-29-desmethyl RA-VII (18) adopt exclusively a single solution conformation that corresponds to the major solution conformations of 8 and 14. This conformation contains a characteristic cis C-30-N-29 amide central to a type VI beta-turn and the cycloisodityrosine subunit, a trans C-8-N-9 amide central to a typical type II beta-turn capped with a tight Ala(4)-NH-O=C-Ala(1) hydrogen bond, and a trans C-14-N-15 N-methyl amide. In sharp contrast, removal of the N-15 methyl group within 16, 17, 19, and 20 results in the adoption of solution conformations possessing the inherently favored trans C-30-N-29 amide central to the cycloisodityrosine (14)-membered subunit. Thus, the N-15-methyl group within 8 is responsible for the agents adoption of the disfavored cis C-30-N-29 amide central to the cycloisodityrosine subunit. Importantly, preceding studies have defined the cycloisodityrosine subunit of 8 as the pharmacophore and, in a reversal of the initially assigned roles, revealed that it is the tetrapeptide housed in the 18-membered ring that induces and maintains the rigid, normally inaccessible cis C-30-N-29 amide conformation within the 14-membered cycloisodityrosine subunit. The studies detailed herein reveal that it is the N-15-methyl group that induces this conformational preference for the disfavored cis C-30-N-29 amide and that its removal results in a major conformational change with adoption of the trans C-30-N-29 amide and a loss of biological activity.Thus, the N-15-methyl group is essential for maintenance of the conformational and biological properties of 8; the N-9-methyl group is not essential, and its removal leads to exclusive population of a single biologically active conformation; and the N-29-methyl group once thought essential td the adoption of the C-30-N-29 cis amide is not essential, and its removal does not alter the conformational or biological properties of 8.
    DOI:
    10.1021/ja00133a010
  • 作为产物:
    参考文献:
    名称:
    N-Desmethyl Derivatives of Deoxybouvardin and RA-VII: Synthesis and Evaluation
    摘要:
    The synthesis of the complete set of seven N-desmethyl derivatives of RA-VII (8) are described. Thus, the synthesis of the four 14-membered cycloisodityrosine derivatives 21-24 and their coupling with the two tetrapeptides 32 and 33 followed by formation of the 18-membered ring with macrocyclization provided the full set of seven desmethyl derivatives 14-20 of RA-VII (8). The solution phase conformational properties of 8 and 14-20 were examined by 1D and 2D H-1 NMR to reveal the role of N-methylation on the key conformational aspects of the natural agents. In contrast to each of the simple cycloisodityrosine derivatives 21-24 which adopt a single, rigid solution conformation possessing a secondary or tertiary trans amide central to the 14-membered ring, the natural agents including 8 adopt a single predominant solution conformation (83-88%) that corresponds closely to the X-ray structure conformation which possesses an inherently disfavored cis C-30-N-29 tertiary amide central to the 14-membered cycloisodityrosine subunit. Moreover, this cis amide is the predominant conformation (85-95%) observed with N-29-desmethyl RA-VII (14) indicating that even a secondary C-30-N-29 amide adopts this inherently disfavored cis amide stereochemistry. The minor conformation of 8 observed in solution (12-17%) is shown to be derived from a minor cis C-8-N-9 tertiary amide which was not observed with its conversion to a secondary amide. Both N-9-desmethyl RA-VII (15) and N-9,N-29-desmethyl RA-VII (18) adopt exclusively a single solution conformation that corresponds to the major solution conformations of 8 and 14. This conformation contains a characteristic cis C-30-N-29 amide central to a type VI beta-turn and the cycloisodityrosine subunit, a trans C-8-N-9 amide central to a typical type II beta-turn capped with a tight Ala(4)-NH-O=C-Ala(1) hydrogen bond, and a trans C-14-N-15 N-methyl amide. In sharp contrast, removal of the N-15 methyl group within 16, 17, 19, and 20 results in the adoption of solution conformations possessing the inherently favored trans C-30-N-29 amide central to the cycloisodityrosine (14)-membered subunit. Thus, the N-15-methyl group within 8 is responsible for the agents adoption of the disfavored cis C-30-N-29 amide central to the cycloisodityrosine subunit. Importantly, preceding studies have defined the cycloisodityrosine subunit of 8 as the pharmacophore and, in a reversal of the initially assigned roles, revealed that it is the tetrapeptide housed in the 18-membered ring that induces and maintains the rigid, normally inaccessible cis C-30-N-29 amide conformation within the 14-membered cycloisodityrosine subunit. The studies detailed herein reveal that it is the N-15-methyl group that induces this conformational preference for the disfavored cis C-30-N-29 amide and that its removal results in a major conformational change with adoption of the trans C-30-N-29 amide and a loss of biological activity.Thus, the N-15-methyl group is essential for maintenance of the conformational and biological properties of 8; the N-9-methyl group is not essential, and its removal leads to exclusive population of a single biologically active conformation; and the N-29-methyl group once thought essential td the adoption of the C-30-N-29 cis amide is not essential, and its removal does not alter the conformational or biological properties of 8.
    DOI:
    10.1021/ja00133a010
点击查看最新优质反应信息

同类化合物

(2R,3R)-4-(蒽-9-基)-3-(叔丁基)-2-甲基-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 黄花菜木脂素B 黄皮树碱 黄小檗碱 鹅掌楸碱 鬼臼酸哌啶基腙氮氧自由基 鬼臼酸 鬼臼脂毒酮 鬼臼毒醇 鬼臼毒素-4-O-葡萄糖苷 鬼臼毒素 鬼臼毒素 高阿莫灵碱 顺式-1,4-二苯基-2-甲氧基-2-丁烯-1,4-二酮 阿罗莫灵 防己诺林碱 防己索林 金不换萘酚 金不换素 里立脂素B二甲醚 连翘脂素 达卡他韦杂质7 赤式-愈创木基甘油-BETA-O-4'-二氢松柏醇 襄五脂素 表鬼臼毒素乙醚 表芝麻素单儿茶酚 表去甲络石甙元 蔚瑞昆森 蒿脂麻木质体 蒽,9,10-二[4-(2,2-二苯基乙烯基)苯基]- 落叶松树脂醇二甲醚 落叶松树脂醇 萘并[2,3-d]-1,3-二噁唑-5(6H)-酮,8-(1,3-苯并二噁唑-5-基)-7,8-二氢-6,7-二甲基-,(6R,7S,8R)-rel-(-)- 萘并[2,3-c]呋喃-1,3-二酮,6-甲氧基-4-(4-甲氧苯基)- 萘并[2,3-c]呋喃-1(3H)-酮,7-羟基-4-(3-甲氧苯基)- 萘并[2,3-c]呋喃-1(3H)-酮,4-(2-氟苯基)-7-(苯基甲氧基)- 萘并[1,2-d]-1,3-二噁唑,9-(1,3-苯并二噁唑-5-基)-6,7-二氢-7,8-二甲基-,(7S)- 萘,1-氯-2-乙基-3-甲基-4-苯基- 荜澄茄素 荜澄茄内酯 荛花酚 苯雌酚二甲醚 苯雌酚 苯酚,5-[2-(3-羟基苯基)乙基]-3-[4-[2-(3-羟基苯基)乙基]苯氧基]-2-甲氧基- 苯酚,4,4'-(四氢-3,4-二甲基-2,5-呋喃二基)二[2-甲氧基-,(2R,3R,4S,5R)-rel-(-)-(9CI) 苯甲醇,4-羟基-3-甲氧基-a-[(1S)-1-[2-甲氧基-4-(1E)-1-丙烯-1-基苯氧基]乙基]-,(aS)- 苯甲醇,3,4-二甲氧基-a-[1-[2-甲氧基-4-(2-丙烯基)苯氧基]乙基]- 苯甲醇,3,4-二甲氧基-a-[1-(2-甲氧基苯氧基)乙基]- 苯甲醇,3,4-二甲氧基-a-[1-(2-甲氧基苯氧基)乙基]- 苯氧基-9苯基-10蒽